All In Biotech

Drug Trial Radar · NCT05881837

A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 249 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

249

Actual

Start

Jun 13, 2023

Primary completion

Oct 13, 2024

Study completion Oct 13, 2024

Sponsor

Sponsor type
Industry
First posted
May 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and dose-response relationship of HRS9531 injection compared with placebo in reducing body weight in obese subjects without diabetes after 24 weeks of treatment.

Conditions

  • Overweight or Obesity

Interventions

  • HRS9531 injectionDrug

    HRS9531 injection: dose level 1 for 32 weeks; level 2 for 20 weeks

  • HRS9531 injectionDrug

    HRS9531 injection: dose level 2

  • HRS9531 injectionDrug

    HRS9531 injection: dose level 3

  • HRS9531 injectionDrug

    HRS9531 injection: dose level 4

  • HRS9531 injection PlaceboDrug

    Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks; HRS9531 injection level 2 for 20 weeks

  • HRS9531 injection PlaceboDrug

    Placebo arm matching active arm HRS9531 injection dose level 2 for 32 weeks; HRS9531 injection level 2 for 20 weeks

  • HRS9531 injection PlaceboDrug

    Placebo arm matching active arm HRS9531 injection dose level 3 for 32 weeks; HRS9531 injection level 2 for 20 weeks

  • HRS9531 injection PlaceboDrug

    Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks; HRS9531 injection level 2 for 20 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weightTime frame: Week 0, Week 24

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Huadu District People's Hospital of Guangzhou

    Guangzhou, Guangdong, China

  • The People's Hospital of Longhua. Shenzhen

    Shenzhen, Guangdong, China

  • Sencond Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China

  • The First Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Nanyang Medical College

    Nanyang, Henan, China

  • The Central Hospital Of Huangshi

    Huangshi, Hubei, China

  • The Third People's Hospital of Hubei Province

    Wuhan, Hubei, China

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China

  • Lianyungang Hospital of TCM

    Lianyungang, Jiangsu, China

  • The First People's Hospital Of Lianyungang

    Lianyungang, Jiangsu, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • North Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, China

  • Shengjing Hospital Of China Medical University

    Shenyang, Liaoning, China

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • Second Hospttoal of Shanxi Medical University

    Taiyuan, Shanxi, China

  • The First Affiliated Hospital of Xi'an Medical College

    Xian, Shanxi, China

  • Chengdu Second People's Hospital

    Chengdu, Sichuan, China

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • The First People's Hospital of Hangzhou

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.